Centrum Medyczne Hcp Sp. z o.o.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The research team at Centrum Medyczne Hcp Sp. z o.o. is conducting studies aimed at improving outcomes for patients with heart conditions. Trials evaluate the safety and long‑term benefits of new therapies for chronic heart failure and address iron deficiency that worsens cardiac health.
- Chronic Heart Failure
- Iron‑deficiency management in heart failure
- Reduction of cardiovascular mortality
- Hospitalization rates for worsening heart failure
These investigations seek to provide evidence for more effective treatment strategies and better quality of life for cardiovascular patients.
Neoplasms
Clinical research at this Polish hospital includes advanced studies on several cancer types. The focus is on testing innovative targeted agents for breast cancer and evaluating new combinations for skin‑derived malignancies.
- Advanced Breast Cancer
- High‑risk HER2‑positive Breast Cancer
- Triple‑negative Breast Cancer
- Resectable cutaneous squamous cell carcinoma
The goal is to determine whether newer therapies can improve survival and reduce disease progression compared with current standards.
Nervous System Diseases
Researchers are exploring treatments that address early motor and pain disorders. Studies examine the efficacy of novel compounds for early Parkinson’s disease and preventive options for patients suffering from frequent migraines.
- Early Parkinson’s Disease
- Episodic Migraine
- Migraine prevention with new agents
- Improvement of motor function scores
These trials aim to slow disease progression and lessen the burden of chronic headache disorders.
Mental Disorders
A broad portfolio of psychiatric studies is underway, targeting both mood and psychotic conditions. The work includes evaluating novel drugs for schizophrenia, bipolar mania, major depression, and neurodevelopmental disorders such as Tourette’s.
- Schizophrenia (negative symptoms and cognition)
- Bipolar I Mania with mixed features
- Major Depressive Disorder
- Tourette’s Disorder
- Agitation associated with Alzheimer’s disease
- Psychosis associated with Alzheimer’s disease
The purpose of these investigations is to identify safer, more effective therapies that improve daily functioning and reduce symptom severity for individuals with mental health challenges.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 5 therapeutic areas and 15 of 42 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 41 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 12 by active trials.
lock +11 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centrum Medyczne Hcp Sp. z o.o.
lock Showing 1 of 29 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21197) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of any body region (except CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs) | Bayer AG | Phase III | Not Recruiting | Sep 2023 | Dec 2024 |
IMP list
lock Showing 1 of 42 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Trospium Chloride | 7 | Unknown | 2024-05-09 | 2026-06-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.